All articles tagged with #medication adherence
A major meta-analysis in The Lancet suggests that while statins cause minor increases in muscle pain, liver enzyme changes, and diabetes risk, they do not significantly cause memory loss, depression, or sleep issues. Most reported muscle complaints are not actually caused by the drug, yet poor adherence remains a critical issue.
A meta-analysis of 91,339 participants across nine randomized trials shows that the cardiovascular protection from antihypertensive medications hinges on consistent dosing: higher adherence (≥80%) yielded greater blood pressure reductions (5.2 vs 3.0 mmHg) and an 11% reduction in major cardiovascular events, while lower adherence offered little benefit. The findings highlight the need for simpler, longer-acting regimens and strategies to improve adherence so patients don’t miss out on life-saving effects.
A meta-analysis of nine randomized trials (over 91,000 adults) found that hypertension patients who take at least 80% of their prescribed blood pressure meds have an 11% lower risk of major cardiovascular events and reduce systolic blood pressure by about 5.2 mmHg, compared with those on placebo or less intensive treatment; those with lower adherence saw no significant risk reduction. The study, soon to be presented at the 2026 European Society of Cardiology Congress and not yet peer‑reviewed, highlights that consistent, sustained medication use yields greater protection and offers strategies to improve adherence (e.g., simplifying regimens, habit stacking, and combination pills).
MIT engineers have developed a biodegradable ingestible capsule with a zinc-cellulose antenna and a micro-RFID chip that emits a real-time signal confirming a pill has been swallowed. The capsule dissolves in the stomach while the RFID component is excreted, enabling noninvasive adherence monitoring for critical therapies (e.g., transplant immunosuppression) and potential integration with health records. The SAFARI project uses safe, eco-friendly materials and aims for human trials, offering a pathway to real-time feedback without bulky wearables.
MIT engineers have developed a biodegradable pill with an embedded RFID system that reports when it has been swallowed, potentially improving medication adherence for patients requiring long-term treatment, with plans for further testing and clinical application.
The article discusses resistant hypertension, a condition where high blood pressure persists despite medication and lifestyle changes, highlighting the importance of proper diagnosis, adherence, and new treatment options like renal denervation, especially in India where hypertension is widespread and often poorly managed.
A Danish study finds that adults with ADHD face significant social and economic challenges by age 30, with limited improvements from medication adherence, highlighting the influence of family background and the need for comprehensive treatment approaches.
A study by Blue Cross Blue Shield found that 58% of people prescribed GLP-1 drugs like Saxenda and Wegovy stopped using them within three months, often due to impatience or side effects, preventing them from seeing the intended weight-loss benefits.
A new study by the Blue Cross Blue Shield Association reveals that over 30% of people taking GLP-1 weight-loss drugs like Ozempic and Wegovy stop their treatment within four weeks, often due to early side effects and high costs. This premature discontinuation is more common among younger adults and those in underserved areas. Experts emphasize the importance of completing at least 12 weeks of treatment to achieve significant weight loss and maintain health benefits, as stopping early often leads to regaining most of the lost weight.
Patients often struggle with nonadherence to prescribed medications, but the new obesity drugs Wegovy and Zepbound are showing exceptional compliance rates among users, with many intending to take them indefinitely. Unlike traditional medications, patients are often the ones seeking out obesity drugs after struggling with weight loss and regain. The drugs, while effective, come with drawbacks such as cost, availability issues, and side effects, but users are willing to endure these challenges due to the significant improvement in their quality of life and the elimination of obesity-related stigma and shame.
Many patients struggle with medication adherence, leading to preventable medical costs and deaths, but the new obesity drugs Wegovy and Zepbound are showing promise in overcoming this issue. Doctors have observed that patients are faithfully taking these drugs, which have been effective in helping people lose weight and keep it off. While some patients may initially hesitate to start due to concerns about regaining weight if they stop, those who do start are reportedly continuing with the medication.
Many patients struggle with medication adherence, leading to preventable medical costs and deaths, but the new obesity drugs Wegovy and Zepbound are showing promise in overcoming this issue. Doctors have observed that patients are faithfully taking these drugs, which have been effective in helping people lose weight and keep it off. While some patients may initially hesitate to start the medication, those who do begin are reportedly continuing with it, indicating a potential breakthrough in addressing medication nonadherence in the treatment of obesity.
A study found that half of the patients using GLP-1 RAs, a class of injected drugs including Ozempic and Mounjaro, quit within a year due to gastrointestinal issues such as nausea, vomiting, and diarrhea. The discontinuation of these medications puts patients at a greater risk for hospitalizations related to diabetes. The study highlights the need for ongoing communication between patients and prescribers to address medication benefits, side effects, and costs.
A study published in JAMA Network Open found that 1 in 5 adults aged 65 and above skipped or delayed their prescription medications last year due to concerns about cost. The study's lead author attributed the increase to rising inflation and prescription drug costs. The findings are in line with earlier studies and real-world experiences. The Inflation Reduction Act aims to lower the high cost of prescription drugs for older adults, but some of its provisions won't go into effect for several more years. Billionaire Mark Cuban's Cost Plus Drug Co. offers some generic drugs at discounted prices.